Evidence map›Paper›PMID 40785348›Full record

ArticleVeterinary dermatology2026

Incidence Rate of Otitis Externa Episodes in Atopic Dogs Is Reduced by a Therapeutic Diet in a 6-Month Randomised, Blinded, Controlled, Clinical Trial.

Adrian Watson, Jeremy Laxalde, Franco Martini, Nina Fischer, Elisa Maina, Claude Favrot

Abstract readRandomized Controlled Trial, Veterinary
In one paragraph

Article in Veterinary dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Adrian WatsonRoyal Canin SAS, Research and Development, Aimargues, France.ORCID https://orcid.org/0000-0002-7623-0457
Jeremy LaxaldeRoyal Canin SAS, Research and Development, Aimargues, France.
Franco MartiniClinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zürich, Zürich, Switzerland.ORCID https://orcid.org/0000-0002-9304-2706
Nina FischerClinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zürich, Zürich, Switzerland.ORCID https://orcid.org/0000-0002-0142-226X
Elisa MainaClinical Veterinary Medicine, Department of Clinical Dermatology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.ORCID https://orcid.org/0009-0004-8255-0563
Claude FavrotClinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zürich, Zürich, Switzerland.ORCID https://orcid.org/0000-0002-0821-0956

Funding

Royal Canin
6 · The paper itself

Abstract

backgroundRecurrent otitis externa (OE) episodes commonly affect dogs with canine atopic dermatitis (cAD) despite ongoing cAD treatment.

objectiveTo determine if a therapeutic diet with active ingredients targeting the skin barrier and allergy pathways reduces the incidence rate of OE. ANIMALS, MATERIALS AND

methodsThirty-four client-owned dogs with active erythroceruminous OE + cAD (not necessarily active) were randomised to test (n = 16) or control diet (n = 18), fed for up to 6 months. Dogs had to be in remission by Month (M)1 after initial OE treatment. Outcomes included incidence rate (percentage of dogs with ≥ 1 OE episode), 0-3 Otitis Index Score (OTIS-3), cAD Extent and Severity Index, 4th iteration (CADESI-04), and medication score (medication required to control OE and/or cAD) at M3 and the end-point, defined as each dog's last on-study data.

resultsThe incidence rate was significantly lower in the test versus control group (25% vs. 61%, p < 0.01). OTIS-3 and CADESI-04 improved significantly between baseline and M3 in both groups (control: p = 0.003 and p < 0.001; test: each p = 0.001). Between M3 and the end-point, OTIS-3 and CADESI-04 rebounded significantly in the control (p = 0.025 and p = 0.026) and not in the test group (p = 0.139 and p = 0.909). CADESI improvement from baseline was maintained at the end-point in the test (p < 0.001) and not in the control group (p = 0.227). Medication score improved significantly throughout the diet duration in the test group (baseline to M3, M3 to end-point, and baseline to end-point) versus no improvements in the control group. CONCLUSION AND CLINICAL RELEVANCE: A therapeutic diet for cAD helped to sustain improvements in aural manifestations.

Indexed as

Dermatitis, AtopicDietDog DiseasesOtitis ExternaAnimal FeedAnimalsDogsFemaleIncidenceMaleatopicdermatitisdietdogsotitis externarecurrence

Identifiers

PMID40785348
PMCPMC12796999

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.